论文部分内容阅读
目的观察培美曲塞联合顺铂治疗晚期非小细胞肺癌的临床疗效和不良反应。方法 26例晚期非小细胞肺癌患者采用培美曲塞500 mg/m2,静脉滴注,第l天;顺铂75 mg/m2,静脉滴注,第l天,2l d为1个周期,2个周期后评价疗效及不良反应。结果全组26例患者均可评价疗效。其中CR 1例,PR 5例,SD 11例,PD 9例,有效率23.1%(6/26)。结论培美曲塞联合顺铂治疗晚期非小细胞肺癌的近期疗效较好,毒副反应低,提高了患者的生活质量。
Objective To observe the clinical efficacy and adverse reactions of pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods 26 cases of advanced non-small cell lung cancer patients with pemetrexed 500 mg / m2, intravenous drip, the first day; cisplatin 75 mg / m2, intravenous drip, the first day, 2l d for a cycle, 2 After a period of evaluation of efficacy and adverse reactions. Results The whole group of 26 patients can evaluate the efficacy. There were 1 case of CR, 5 cases of PR, 11 cases of SD and 9 cases of PD with an effective rate of 23.1% (6/26). Conclusion Pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer has good curative effect in the near future, low toxicity and improved quality of life.